Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation

Những quyển sách tương tự

• Detection of crizotinib-sensitive lung adenocarcinomas with MET, ALK and ROS1 genomic alterations via comprehensive genomic profiling
  Bằng: Le, Xiuning, et al.
  Được phát hành: (2015)
• Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy
  Bằng: Rangachari, Deepa, et al.
  Được phát hành: (2017)
• Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% expression in lung adenocarcinoma
  Bằng: Rangachari, Deepa, et al.
  Được phát hành: (2017)
• Lazarus-type response to crizotinib in a patient with poor performance status and advanced MET exon 14 skipping mutation-positive lung adenocarcinoma
  Bằng: Shea, Meghan, et al.
  Được phát hành: (2016)
• Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
  Bằng: Sehgal, Kartik, et al.
  Được phát hành: (2018)